tetano
Editor, Senior Moderator
Vaccine
. 2023 Jul 18;S0264-410X(23)00741-7.
doi: 10.1016/j.vaccine.2023.06.056. Online ahead of print. Vaccine effectiveness of recombinant and standard dose influenza vaccines against influenza related hospitalization using a retrospective test-negative design
Richard K Zimmerman[SUP] 1 [/SUP], Mary Patricia Nowalk[SUP] 2 [/SUP], Klancie Dauer[SUP] 3 [/SUP], Lloyd Clarke[SUP] 4 [/SUP], Jonathan M Raviotta[SUP] 1 [/SUP], G K Balasubramani[SUP] 3 [/SUP]
Affiliations
Background: Relative effectiveness of various vaccine formulations provide important input for vaccine policy decisions and provider purchasing decisions. We used electronic databases to conduct a test-negative case control study to determine relative vaccine effectiveness (rVE) of recombinant influenza vaccine (RIV4) compared with standard dose vaccines (SD-IIV4) against influenza hospitalization.
Methods: Adults 18-64 and ≥65 years of age hospitalized in a large U.S. health system (19 hospitals) in 2018-2019 and 2019-2020 who were clinically tested for influenza using reverse transcription polymerase chain reaction (RT-PCR) assays were included. The hospital system electronic medical record (EMR) and the state immunization registry were used to confirm influenza vaccination. Propensity scores with inverse probability weighting were used to adjust for potential confounders and determine rVE.
Results: Of the 14,590 individuals included in the primary analysis, 3,338 were vaccinated with RIV4 and 976 were vaccinated with SD-IIV4, with the balance of 10,276 being unvaccinated. Most participants were white (80 %), most (70 %) had a high-risk condition, just over half were female (54 %) and age 65 years or older (53 %). Overall RIV4 rVE was significant when adjusted for propensity scores with inverse probability weights (rVE = 31; 95 % CI = 11 %, 46 %). Among younger adults (18-64 years-old), overall rVE of RIV4 was significant (rVE = 29; 95 % CI = 4 %, 47 %).
Conclusions: Over all adults, both RIV4 and SD-IIV4 were effective against influenza hospitalization, with RIV4 providing better protection compared with SD-IIV4 overall, for females, younger adults, and those with no high-risk conditions.
Keywords: Hospitalization; Influenza; Influenza vaccines; Vaccine effectiveness.
. 2023 Jul 18;S0264-410X(23)00741-7.
doi: 10.1016/j.vaccine.2023.06.056. Online ahead of print. Vaccine effectiveness of recombinant and standard dose influenza vaccines against influenza related hospitalization using a retrospective test-negative design
Richard K Zimmerman[SUP] 1 [/SUP], Mary Patricia Nowalk[SUP] 2 [/SUP], Klancie Dauer[SUP] 3 [/SUP], Lloyd Clarke[SUP] 4 [/SUP], Jonathan M Raviotta[SUP] 1 [/SUP], G K Balasubramani[SUP] 3 [/SUP]
Affiliations
- PMID: 37474406
- DOI: 10.1016/j.vaccine.2023.06.056
Background: Relative effectiveness of various vaccine formulations provide important input for vaccine policy decisions and provider purchasing decisions. We used electronic databases to conduct a test-negative case control study to determine relative vaccine effectiveness (rVE) of recombinant influenza vaccine (RIV4) compared with standard dose vaccines (SD-IIV4) against influenza hospitalization.
Methods: Adults 18-64 and ≥65 years of age hospitalized in a large U.S. health system (19 hospitals) in 2018-2019 and 2019-2020 who were clinically tested for influenza using reverse transcription polymerase chain reaction (RT-PCR) assays were included. The hospital system electronic medical record (EMR) and the state immunization registry were used to confirm influenza vaccination. Propensity scores with inverse probability weighting were used to adjust for potential confounders and determine rVE.
Results: Of the 14,590 individuals included in the primary analysis, 3,338 were vaccinated with RIV4 and 976 were vaccinated with SD-IIV4, with the balance of 10,276 being unvaccinated. Most participants were white (80 %), most (70 %) had a high-risk condition, just over half were female (54 %) and age 65 years or older (53 %). Overall RIV4 rVE was significant when adjusted for propensity scores with inverse probability weights (rVE = 31; 95 % CI = 11 %, 46 %). Among younger adults (18-64 years-old), overall rVE of RIV4 was significant (rVE = 29; 95 % CI = 4 %, 47 %).
Conclusions: Over all adults, both RIV4 and SD-IIV4 were effective against influenza hospitalization, with RIV4 providing better protection compared with SD-IIV4 overall, for females, younger adults, and those with no high-risk conditions.
Keywords: Hospitalization; Influenza; Influenza vaccines; Vaccine effectiveness.